Cardiovascular Effects of Incretins in Diabetes

Canadian Journal of Diabetes

Volumn 37, Issue 5, 2013, Pages 309-314

  Advani, Andrew ^a   Bugyei Twum, Antoinette ^a   Connelly, Kim A ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cardiac function; Dipeptidyl peptidase 4; Glucagon like peptide 1; Incretin; Stromal cell derived factor 1

Indexed keywords

ALOGLIPTIN; CHEMOKINE RECEPTOR CXCR4; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INCRETIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1ALPHA; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; VENOM;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; MEDICAL LITERATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN LOCALIZATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; WEIGHT REDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; FEMALE; HEART MUSCLE CELL; MALE; METABOLISM; VASCULAR ENDOTHELIUM;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIUM, VASCULAR; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MYOCYTES, CARDIAC; PEPTIDES; TREATMENT OUTCOME; VENOMS;

EID: 84884691174     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.06.010     Document Type: Review

References (69)

1. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
2. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2011. Diabetes Res Clin Pract 2013, 100:277-279. IDF Diabetes Atlas Group.
3. Doucet G., Beatty M. The cost of diabetes in Canada: the economic tsunami. Can J Diabetes 2010, 34:27-29.
4. Elrick H., Stimmler L., Hlad C.J., et al. Plasma insulin response to oral and intravenous glucose administration. JClin Endocrinol Metab 1964, 24:1076-1082.
5. Brown J.C., Dryburgh J.R. Agastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem 1971, 49:867-872.
6. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin system. Endocr Rev 2012, 33:187-215.
7. Phillips L.K., Prins J.B. Update on incretin hormones. Ann N Y Acad Sci 2012, 1243:E55-E74.
8. Asmar M., Holst J.J. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances. Curr Opin Endocrinol Diabetes Obes 2010, 17:57-62.
9. Drucker D.J., Philippe J., Mojsov S., et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987, 84:3434-3438.
10. Mojsov S., Weir G.C., Habener J.F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. JClin Invest 1987, 79:616-619.
11. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
12. Drucker D.J. The biology of incretin hormones. Cell Metab 2006, 3:153-165.
13. Riddle M.C., Drucker D.J. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006, 29:435-449.
14. Bullock B.P., Heller R.S., Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996, 137:2968-2978.
15. Vila Petroff M.G., Egan J.M., Wang X., et al. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001, 89:445-452.
16. Xiao Y.-F., Nikolskaya A., Jaye D.A., et al. Glucagon-like peptide-1 enhances cardiac L-type Ca. Cardiovasc Diabetol 2011, 10:6.
17. Noyan-Ashraf M.H., Momen M.A., Ban K., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
18. Abu-Hamdah R., Rabiee A., Meneilly G.S., et al. The extrapancreatic effects of glucagon-like peptide-1 and related peptides. JClin Endocrinol Metab 2009, 94:1843-1852.
19. Ban K., Noyan-Ashraf M.H., Hoefer J., et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
20. Shigeta T., Aoyama M., Bando Y.K., et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 2012, 126:1838-1851.
21. Fadini G.P., Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011, 55:10-16.
22. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 invitro and invivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
23. Kirby M., Yu D.M.T., O'Connor S.P., et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 2009, 118:31-41.
24. Connelly K.A., Zhang Y., Advani A., et al. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodelling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther 2012, Epub ahead of print.
25. Deacon C.F., Plamboeck A., Møller S., et al. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 2002, 282:E873-E879.
26. Meier J.J., Gethmann A., Nauck M.A., et al. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab 2006, 290:E1118-E1123.
27. Vahl T.P., Paty B.W., Fuller B.D., et al. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. JClin Endocrinol Metab 2003, 88:1772-1779.
28. Tomas E., Stanojevic V., Habener J.F. GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011, 167:177-184.
29. Shao W., Wang Z., Ip W., et al. GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin induced diabetes mice and activates PKA-β-catenin signaling in beta-cells invitro. Am J Physiol Endocrinol Metab 2013, Epub ahead of print.
30. Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007, 30:1335-1343.
31. Gros R., You X., Baggio L.L., et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003, 144:2242-2252.
32. Nikolaidis L.A., Elahi D., Shen Y.-T., et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289:H2401-H2408.
33. Nikolaidis L.A. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961.
34. Timmers L., Henriques J.P., de Kleijn D.P., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. JAm Coll Cardiol 2009, 53:501-510.
35. Kristensen J., Mortensen U.M., Schmidt M., et al. Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 2009, 9:31.
36. Sokos G.G., Nikolaidis L.A., Mankad S., et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. JCard Fail 2006, 12:694-699.
37. Nikolaidis L.A., Mankad S., Sokos G.G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
38. Lonborg J., Vejlstrup N., Kelbaek H., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012, 33:1491-1499.
39. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. NEngl J Med 1991, 325:1468-1475.
40. Fox K., Ford I., Steg P.G., et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008, 372:817-821.
41. Yamamoto H., Lee C.E., Marcus J.N., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. JClin Invest 2002, 110:43-52.
42. Kim M., Platt M.J., Shibasaki T., et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013, 19:567-575.
43. Gustavson S.M., Chen D., Somayaji V., et al. Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011, 13:1056-1058.
44. Pratley R., Nauck M., Bailey T., et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011, 65:397-407.
45. Halbirk M., Nørrelund H., Møller N., et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010, 298:H1096-H1102.
46. Yang W., Chen L., Ji Q., et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Diabetes Obes Metab 2011, 13:81-88.
47. Gallwitz B., Vaag A., Falahati A., et al. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 2009, 64:267-276.
48. Segal M.S., Shah R., Afzal A., et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 2006, 55:102-109.
49. Lee S.A., Kim Y.R., Yang E.J., et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. JClin Endocrinol Metab 2013, 98:2553-2561.
50. Sauvé M., Ban K., Momen M.A., et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010, 59:1063-1073.
51. Zaruba M.-M., Franz W.-M. Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy. Expert Opin Biol Ther 2010, 10:321-335.
52. Ceradini D.J., Kulkarni A.R., Callaghan M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10:858-864.
53. Askari A.T., Unzek S., Popović Z.B., et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
54. Saxena A., Fish J.E., White M.D., et al. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation 2008, 117:2224-2231.
55. Segers V.F.M., Tokunou T., Higgins L.J., et al. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007, 116:1683-1692.
56. Penn M.S., Mendelsohn F.O., Schaer G.L., et al. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res 2013, 112:816-825.
57. Theiss H.D., Vallaster M., Rischpler C., et al. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis. Stem Cell Res 2011, 7:244-255.
58. Gilbert R.E. The potential for cardiac protection with DPP4 inhibition: the stromal cell-derived factor-1 (SDF-1α) hypothesis. JDiabetes 2013, Epub ahead of print.
59. Zaruba M.-M., Theiss H.D., Vallaster M., et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009, 4:313-323.
60. Connelly K.A., Zhang Y., Advani A., et al. 776 DPP-4 inhibition improves cardiac function following experimental myocardial infarction: potential non-Glp-1 mediated effects. Can J Cardiol 2012, 28:S397-S398.
61. Frederich R., Alexander J., Fiedorek F., et al. Asystematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010, 122:16-27.
62. Monami M., Ahrén B., Dicembrini I., et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2012, 15:112-120.
63. Monami M., Genovese S., Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomised clinical trials. Diabetes Obes Metab 2013, Epub ahead of print.
64. Marso S.P., Lindsey J.B., Stolker J.M., et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies. Diabetes Vasc Dis Res 2011, 8:237-240.
65. Ratner R., Han J., Nicewarner D., et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011, 10:22.
66. Monami M., Cremasco F., Lamanna C., et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011, 2011:1-10.
67. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. NEngl J Med 2007, 356:2457-2471.
68. FDA Guidance for Industry. n.d. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
69. Mosenzon O., Raz I., Scirica B.M. Baseline characteristics of the patient population in the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus (SAVOR)-TIMI 53. Diabetes Metab Res Rev 2013, 29:417-426.